Phase I dose-escalation study of nab-paclitaxel combined with cisplatin and capecitabin as induction chemotherapy followed by concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma
Nasopharyngeal carcinoma (NPC) is a malignant type of cancer arising from the nasopharynx epithelium, which is different from head and neck cancers because of its distinct geographical distribution, high correlation with the Epstein-Barr virus (EBV), and unique pathological types[1]. Radiotherapy is a radical therapy for patients with NPC, with more than 70% of patients having locally advanced disease at first diagnosis; cisplatin concurrent chemotherapy combined with radiotherapy is the cornerstone for locally advanced NPC[2].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Yu-Chen, Mei-Juan Luo, Rong-Ping Liu, Jing Jin, Sheng-Wen Deng, Lin-Quan Tang, Xiao-Yun Li, Li-Ting Liu, Dong-Hua Luo, Rui Sun, Sai-Lan Liu, Ji-Bin Li, Qing Liu, Pan Wang, Qiu-Yan Chen, Hai-Qiang Mai, Shan-Shan Guo Tags: Original Article Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Head and Neck Cancer | Nasopharyngeal Cancer | Radiology | Study